Apr 10 |
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
|
Apr 10 |
Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
|
Apr 10 |
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
|
Apr 10 |
Nurix Therapeutics GAAP EPS of -$0.76 beats by $0.04, revenue of $16.59M misses by $0.5M
|
Apr 10 |
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
|
Apr 9 |
Nurix gains after extending Sanofi research pact
|
Apr 9 |
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
|
Apr 9 |
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
|
Apr 4 |
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
|
Apr 2 |
Gilead, Nurix extend research pact for two years
|